Therorna

Therorna was founded in China in 2021, leveraging its proprietary circular RNA technology platform to develop next-generation vaccines and innovative therapies.

Compared with linear RNA, circular RNA (circRNA) offers benefits in expression, stability, immunogenicity, and production. Thanks to its structure, circRNA as a tool for protein expression has been proven to maintain a relatively stable protein expression level in vivo for a longer time, which is expected to expand the application scenarios of RNA therapy.

Therorna raised Series A funding in June 2022 to help accelerate the development of a new broad-spectrum COVID-19 vaccine and the discovery of additional novel therapies for a variety of diseases. The company says it has already established a strong pipeline of novel prophylactic and therapeutic drugs aiming to address high unmet medical needs.

The company’s founder Wensheng Wei is a Professor at Peking University and previously also founded genome editing company EdiGene.

Subscribe for alerts on new companies featured on Startups.Bio

hC Bioscience
hC Bioscience is developing Transfer RNA-based therapeutics targeting protein dysfunction. Transfer RNA (tRNA) is a small RNA molecule that plays a key role in protein synthesis. tRNA serves as a …
Melius Pharma
Melius Pharma is a Swedish company founded in 2021 focused on the development of new treatments for interstitial lung diseases. The company's lead project for chronic cough in idiopathic pulmonary …
Tamarix Pharma
Tamarix Pharma was founded in 2021 based on technology licensed from the National Institute for Biotechnology in the Negev (Israel) and is focused on developing novel technologies that restore physiological …
BacVax
BacVax is a spin-off from the University of Arizona with a novel approach to developing vaccines against bacterial infections by mapping the proteins on the surface of bacteria. BacVax's approach …

View all recently featured startups

Tags: